PLK2 and neoplasm: Figure 5(A) provides an overview of the cellular composition at the single-cell level in primary tumours from 11 patients. Figure 5(B) shows that the nine potential drug targets were expressed in multiple cell types, including tumour cells and the expression of the markers PLK2 and VEGFA was particularly prominent in endothelial cells. Additionally, the cell type distribution of representative samples in each immune group is shown in Figure 5(C–E).